Graham Capital Management L.P. Takes $1.02 Million Position in Progyny, Inc. $PGNY

Graham Capital Management L.P. purchased a new stake in shares of Progyny, Inc. (NASDAQ:PGNY) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 45,664 shares of the company’s stock, valued at approximately $1,020,000. Graham Capital Management L.P. owned about 0.05% of Progyny as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. New York State Teachers Retirement System boosted its holdings in shares of Progyny by 0.7% in the first quarter. New York State Teachers Retirement System now owns 73,200 shares of the company’s stock worth $1,635,000 after buying an additional 500 shares during the last quarter. Voya Investment Management LLC boosted its holdings in shares of Progyny by 1.4% in the fourth quarter. Voya Investment Management LLC now owns 51,792 shares of the company’s stock worth $893,000 after buying an additional 701 shares during the last quarter. Polen Capital Management LLC boosted its holdings in shares of Progyny by 0.3% in the first quarter. Polen Capital Management LLC now owns 261,506 shares of the company’s stock worth $5,842,000 after buying an additional 798 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Progyny by 0.4% in the first quarter. Invesco Ltd. now owns 275,936 shares of the company’s stock worth $6,164,000 after buying an additional 1,117 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Progyny in the first quarter worth approximately $44,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Transactions at Progyny

In other news, Director Cheryl Scott sold 2,675 shares of the business’s stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total value of $59,037.25. Following the transaction, the director owned 14,112 shares of the company’s stock, valued at approximately $311,451.84. The trade was a 15.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Allison Swartz sold 2,398 shares of the business’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total transaction of $55,058.08. Following the completion of the transaction, the executive vice president directly owned 79,697 shares in the company, valued at $1,829,843.12. This trade represents a 2.92% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,971 shares of company stock valued at $224,253. 9.40% of the stock is currently owned by corporate insiders.

Progyny Price Performance

Shares of NASDAQ:PGNY opened at $23.54 on Thursday. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $26.76. The company has a market capitalization of $2.02 billion, a P/E ratio of 39.90, a P/E/G ratio of 1.94 and a beta of 1.33. The firm’s 50 day simple moving average is $22.88 and its two-hundred day simple moving average is $22.23.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a return on equity of 10.69% and a net margin of 4.28%.The company had revenue of $332.87 million during the quarter, compared to analysts’ expectations of $315.70 million. During the same period last year, the firm posted $0.17 EPS. Progyny’s quarterly revenue was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, sell-side analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PGNY has been the topic of a number of research reports. Leerink Partnrs raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 8th. Canaccord Genuity Group raised their price objective on shares of Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 20th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Truist Financial raised their target price on shares of Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Thursday, July 17th. Finally, Raymond James Financial set a $28.00 price target on shares of Progyny in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Progyny currently has an average rating of “Moderate Buy” and an average target price of $25.30.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.